SCHEMBL19209529

SCHEMBL19209529

Nc1ncnc2c1[nH]c(=O)n2C1CCN(C(=O)O)CC1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TLR7 Q9NYK1 1/20 0.41
▸ EEF2K O00418 1/20 0.40
▸ JAK2 O60674 3/20 0.39
▸ JAK3 P52333 3/20 0.39
▸ JAK1 P23458 1/20 0.39
▸ BTK Q06187 4/20 0.37
▸ PIK3CD O00329 2/20 0.37
▸ PIK3CA P42336 1/20 0.37
▸ PIK3CG P48736 1/20 0.37
▸ AMD1 P17707 1/20 0.36
▸ ERBB2 P04626 1/20 0.36
▸ LCK P06239 1/20 0.36
▸ TEC P42680 1/20 0.36
▸ TXK P42681 1/20 0.36
▸ BLK P51451 1/20 0.36
▸ BMX P51813 1/20 0.36
▸ ERBB4 Q15303 1/20 0.36
▸ GP6 Q9HCN6 1/20 0.36
▸ EGFR P00533 1/20 0.36
▸ SRC P12931 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20480733 0.93 BTK (0.42) TLR7EEF2KJAK2JAK3JAK1
SCHEMBL16143478 0.93 BTK (0.42) TLR7EEF2KJAK2JAK3JAK1
SCHEMBL15156546 0.86 EGFR (0.44) JAK2JAK3JAK1BTKLCK
SCHEMBL23803929 0.84 ADORA3 (0.49) TLR7EEF2KPIK3CDPIK3CAPIK3CG
SCHEMBL28881338 0.83 SRC (0.50) PIK3CDEGFRSRC
SCHEMBL25269666 0.81 MTOR (0.44) TLR7JAK2JAK3JAK1PIK3CD
SCHEMBL30563726 0.80 TLR7 (0.44) TLR7EEF2KAMD1NSD2NSD3
SCHEMBL18618395 0.80 BTK (0.55) TLR7BTKERBB2LCKTEC
SCHEMBL15156055 0.79 SRC (0.55) PIK3CDPIK3CAEGFRSRC
SCHEMBL15145742 0.79 SRC (0.55) PIK3CDPIK3CAEGFRSRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2017134685-A2 NOVEL HYDRAZINO COMPOUNDS AS BTK INHIBITORS SUN PHARMA ADVANCED RESEARCH COMPANY LIMITED (IN) 2017-08-10 — — WO disclosed
Send feedback